Clinical Trial Update: A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 study of pegylated rhG-CSF as support for advanced non-small cell lung cancer patients undergoing chemotherapy; trial status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pegylated rhG-CSF (pegfilgrastim)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: NSCLC, Neutropenia | Phase 3 | Status: UNKNOWN